Spun out of research at the University of Basel, NanoZymeX is developing a lipid nanoparticle-based delivery platform designed to transport therapeutic enzymes into target cells and lysosomes. The company aims to enhance intracellular delivery and reduce immune reactions to increase functional enzyme activity in affected tissues, targeting lysosomal storage disorders such as Pompe disease. Early preclinical studies reported by the company show strong delivery efficiency and improved enzyme activity in relevant tissues. NanoZymeX plans to use its recent early funding to advance preclinical work, scale manufacturing processes, and prepare for future fundraising and clinical trials. The company intends to partner with pharmaceutical and biotechnology firms to adapt its platform across multiple rare diseases.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026